Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

In vivo BCMA CAR-T therapy shows durable responses up to 15 months in relapsed/refractory multiple myeloma with a 100% initial response rate.

• Why it matters: Long-term safety and efficacy data for in vivo CAR-T treatments are limited, hindering their broader clinical application and optimization for multiple myeloma patients.
• What they did: Researchers followed four patients for up to 15 months, assessing safety, response durability, and pharmacokinetics, with all experiencing cytokine release syndrome and hematotoxicities.
• The result: One patient maintained a complete response for 15 months, while overall median progression-free survival was 4 months; findings highlight safety and the need for platform optimization.